As reports show, with the expiry of Novo Nordisks semaglutide exclusivity on January 4, 2026, Canada has emerged as the first major Western market where generic semaglutide can be legally produced and sold, subject to Health Canada approval
PubMed 40756949 Stable gastric pentadecapeptide BPC 157 as a therapy for the disabled myotendinous junctions in rats
About The Authors: Brandon Miller is a data-driven, people-focused health equity strategist and organizational transformation leader at Clarkston Consulting
The situation becomes more concerning for diabetic patients using these medications, as their risk of intestinal obstruction jumps 4.5 times higher compared to those using other glucose control options
NLRP3 inflammasome suppression
As a result of their specific nature, they are safe and well-tolerated